Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The new pneumococcal vaccine.

S K Obaro1

  • 1Department of Paediatrics, Imperial College School of Medicine, London, W2 1PG, UK. s.obaro@ic.ac.uk

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|October 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2005
Same author

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children.

The Lancet. Infectious diseases·2004
Same author

Vaccines for children: policies, politics and poverty.

Vaccine·2003
Same author

Protein conjugate vaccines--how much is enough?

Trends in microbiology·2001
Same author

Evaluation of Binax now Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus.

The Pediatric infectious disease journal·2001
Same author

Respiratory diseases in Africa: causes and effects.

Lancet (London, England)·2001

Pneumococcal conjugate vaccines offer new hope against the leading bacterial cause of childhood illness worldwide. These vaccines show remarkable efficacy in young children, paving the way for global control of pneumococcal disease.

Area of Science:

  • Pediatrics
  • Vaccinology
  • Infectious Diseases

Background:

  • Pneumococcal disease is the leading vaccine-preventable bacterial illness in children globally.
  • Current polysaccharide vaccines have limited effectiveness in children under two years old.
  • Rising rates of multiresistant Streptococcus pneumoniae strains necessitate new vaccine strategies.

Purpose of the Study:

  • To review the development and impact of pneumococcal conjugate vaccines.
  • To highlight the success of conjugate vaccines in controlling invasive pneumococcal disease.
  • To discuss the future of pneumococcal vaccine research and deployment.

Main Methods:

  • Review of existing literature on pneumococcal vaccines.
  • Analysis of the efficacy of pneumococcal conjugate vaccines in infants and toddlers.

Related Experiment Videos

  • Examination of global trends in pneumococcal disease and antibiotic resistance.

    • Main Results:

    • A seven-valent pneumococcal conjugate vaccine demonstrated remarkable efficacy in US infants and toddlers.
    • The first pneumococcal conjugate vaccine was licensed in February 2000.
    • Widespread adoption of this vaccine is anticipated in countries with need and resources.

    Conclusions:

    • Pneumococcal conjugate vaccines represent a significant advancement in preventing childhood bacterial disease.
    • Continued global surveillance and research into new vaccine formulations are crucial.
    • These vaccines hold promise for substantially reducing the burden of invasive pneumococcal disease worldwide.